|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 134,700.00 KRW | +1.13% |
|
+1.05% | +21.24% |
| 12-03 | Eckert & Ziegler sign supply agreement with SK Biopharmaceuticals | RE |
| 12-03 | Eckert & Ziegler and SK Biopharmaceuticals Sign Actinium-225 Supply Agreement | CI |
| Capitalization | 10,353B 7.05B 6B 5.61B 5.27B 9.71B 640B 10.61B 65.42B 25.29B 301B 26.46B 25.9B 1,095B | P/E ratio 2025 * |
58.2x | P/E ratio 2026 * | 38.4x |
|---|---|---|---|---|---|
| Enterprise value | 10.06B 6.85M 5.83M 5.45M 5.12M 9.43M 622M 10.31M 63.57M 24.57M 293M 25.71M 25.17M 1.06B | EV / Sales 2025 * |
14.1x | EV / Sales 2026 * | 10.9x |
| Free-Float |
35.81% | Yield 2025 * |
-
| Yield 2026 * | 0.08% |
| 1 day | +1.13% | ||
| 1 week | +1.05% | ||
| Current month | -3.65% | ||
| 1 month | +4.99% | ||
| 3 months | +20.92% | ||
| 6 months | +49.17% | ||
| Current year | +21.24% |
| 1 week | 131,000 |  | 139,100 |
| 1 month | 122,100 | | 144,100 |
| Current year | 86,900 | | 144,100 |
| 1 year | 86,900 | | 144,100 |
| 3 years | 57,600 | | 144,100 |
| 5 years | 50,900 | | 181,500 |
| 10 years | 50,900 | | 269,500 |
| Manager | Title | Age | Since |
|---|---|---|---|
Dong-Hoon Lee
CEO | Chief Executive Officer | 57 | 2022-12-31 |
Ji-Young Jeong
DFI | Director of Finance/CFO | 52 | - |
Chang-Ho Yu
PRN | Corporate Officer/Principal | 50 | - |
| Director | Title | Age | Since |
|---|---|---|---|
Hae-Young Ahn
BRD | Director/Board Member | 68 | 2019-08-26 |
Min-Seop Song
BRD | Director/Board Member | 55 | 2019-08-26 |
Min-Ji Kim
BRD | Director/Board Member | 53 | 2023-03-27 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 0.08% | 21 M€ | +23.57% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +1.13% | +1.05% | +27.20% | +80.32% | 7.19B | |
| +1.96% | +3.35% | -13.29% | -32.67% | 60.54B | |
| +0.41% | +2.60% | +7.15% | -16.60% | 8.68B | |
| -0.72% | +2.30% | +31.78% | +11.32% | 7.46B | |
| -0.26% | +0.52% | -2.59% | +115.51% | 5.93B | |
| +0.09% | -1.92% | +192.38% | +62.39% | 4.4B | |
| -2.45% | -3.58% | -14.90% | -6.87% | 2.78B | |
| +1.00% | +5.55% | +31.38% | +29.57% | 2.71B | |
| -4.41% | -6.28% | +13.94% | +42.40% | 2.4B | |
| -0.78% | -0.97% | -16.97% | +4.30% | 1.95B | |
| Average | -0.44% | -1.09% | +25.61% | +28.97% | 10.4B | |
| Weighted average by Cap. | +1.09% | -0.48% | +5.43% | -3.17% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 712B 485M 412M 386M 362M 667M 43.98B 729M 4.5B 1.74B 20.7B 1.82B 1.78B 75.27B | 906B 617M 525M 491M 461M 849M 55.97B 928M 5.72B 2.21B 26.34B 2.32B 2.27B 95.8B |
| Net income | 178B 121M 103M 96.43M 90.56M 167M 10.99B 182M 1.12B 435M 5.17B 455M 445M 18.82B | 270B 184M 156M 146M 137M 253M 16.66B 276M 1.7B 659M 7.84B 689M 675M 28.52B |
| Net Debt | -293B -199M -170M -159M -149M -275M -18.09B -300M -1.85B -715M -8.52B -748M -733M -30.97B | -503B -342M -291M -272M -256M -471M -31.05B -515M -3.18B -1.23B -14.62B -1.28B -1.26B -53.15B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-12-16 | 132,200.00 ₩ | -1.86% | 119,440 |
| 25-12-15 | 134,700.00 ₩ | +1.13% | 198,857 |
| 25-12-12 | 133,200.00 ₩ | -1.84% | 306,780 |
| 25-12-11 | 135,700.00 ₩ | -0.29% | 260,187 |
| 25-12-10 | 136,100.00 ₩ | +0.74% | 151,433 |
End-of-day quote Korea S.E., December 14, 2025
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- A326030 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition